睿知中国疾病研究地图
候选清单0

兰州

甘肃省人民医院

Gansu Provincial Hospital

在本站收录的 53 种疾病中,这家医院列在其中 13 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

甘肃省人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma2 篇牵头论文
  2. 胃癌Stomach cancer76 篇牵头论文
  3. 骨肉瘤Osteosarcoma7 篇牵头论文
  4. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  5. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  6. 多发性骨髓瘤Multiple myeloma3 篇牵头论文
  7. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
  8. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  9. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
  10. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  11. IgA 肾病IgA nephropathy0 篇牵头论文
  12. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
  13. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:鼻咽癌、肝细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、特发性肺纤维化、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.07%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

兰州有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 76 篇,占 0.8%。

牵头论文
76
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 8820222023: 191920232024: 202020242025: 20202025

兰州有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2025-04
    登记号
    NCT06925243

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心兰州、广州

  3. 正在招募
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2025-05
    登记号
    NCT06949033

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心兰州、广州

  4. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术影像与人工智能腹膜转移与晚期
论文中的科室肿瘤内科普外/肝胆胰外科消化/肝病科病理/检验科
牵头的论文76
  1. EBV-miR-BART14-3p Targets LACTB to Enhance Gastric Cancer Cell Proliferation and Migration.2026Biochemical genetics
  2. Optimal artificial intelligence model based on gastrointestinal filling contrast-enhanced ultrasound: Risk stratification of gastric gastrointestinal stromal tumors.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Clinical application and observation of 5G remote robotic radical gastrectomy for gastric cancer.2026Surgical endoscopy
  4. Comprehensive Analysis of Potential Common Pathogenic Mechanisms for COVID-19 Infection and Gastric Cancer.2025Analytical cellular pathology (Amsterdam)免费全文
  5. Meta-analysis of the efficacy of applying reduced surgery for the treatment of asymptomatic unresectable advanced gastric cancer.2025BMC gastroenterology免费全文
  6. CBX2 and EZH2 cooperatively contribute to 5-Fu resistance in gastric cancer by suppressing ferroptosis via trimethylation of H3k27.2025Cellular signalling
  7. Correlation between Metabolic Syndrome and Gastric Cancer: Results of an Evidence-Based Strategy in Oriental Populations.2025Combinatorial chemistry & high throughput screening
  8. Expression, Characteristics, and Clinical Target Prediction of PIK3C3/ vps34 in Gastric Cancer.2025Current cancer drug targets
  9. Downregulation of LncRNA CCAT1 Enhances Chemosensitivity in Cisplatin-Resistant Gastric Cancer Cells.2025Drug development research
  10. Robotic versus laparoscopic gastrectomy for gastric cancer in asia: A meta-analysis of short-term outcomes from six randomized controlled trials.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Spectral computed tomography-based quantitative parameters combined with extracellular volume fraction to predict lymph node metastases in gastric cancer.2025European radiology
  12. Microbiota and gastric cancer: from molecular mechanisms to therapeutic strategies.2025Frontiers in cellular and infection microbiology免费全文
  13. Inflammatory factors collaboratively link Helicobacter pylori-induced gastritis to gastric cancer.2025Frontiers in immunology免费全文
  14. Identification and validation VAT1 in gastric cancer through bioinformatics and experimental analysis.2025International immunopharmacology
  15. LncRNA SNHG14 Regulated by ZNF460 Promotes Gastric Cancer Progression and Metastasis by Targeting the miR-206/FNDC3A Axis.2025Journal of cellular and molecular medicine免费全文
  16. PYGO1 drives gastric cancer progression via the ITGB1/CD47 axis and is therapeutically targeted by pentagalloylglucose.2025Journal of translational medicine免费全文
  17. Construction and validation of a nomogram prediction model for the occurrence of complications in patients following robotic radical surgery for gastric cancer.2025Langenbeck's archives of surgery
  18. Correlation between dyslipidaemia and gastric cancer: pathogenesis to prevention and treatment strategies.2025Lipids in health and disease免费全文
  19. EBV-miR-BART5-5p regulates RORA to promote proliferation and migration of gastric cancer cells.2025PloS one免费全文
  20. MT1JP/miR-103a-3p induce pyroptosis and regulate the tumor immune microenvironment in gastric cancer.2025Scientific reports免费全文
  21. Targeting YBX1: A novel therapeutic strategy for gastric cancer through regulation of cellular senescence and mTOR signaling.2025Tissue & cell
  22. Challenges in clinical translation of artificial intelligence and real-time imaging navigation in radical gastrectomy.2025World journal of gastroenterology免费全文
  23. A pilot study on the clinical feasibility of 5G remote robot-assisted gastrectomy.2025World journal of surgical oncology免费全文
  24. Correlation of the apoptosis in the mitochondrial pathway with the JAK2/STAT3 signaling pathway regarding the effect of Agaricus blazei Murill extract FA-2-b-β in inhibiting the proliferation of gastric cancer cells.2024Asian journal of surgery
  25. Agaricus blazei Murill extract FA-2-b-β inhibits gastric cancer cell proliferation through the mechanisms of cell-cycle blocking and apoptosis by the mitochondrial pathway.2024Asian journal of surgery
  26. Letter to the Editor on "Programmed 'seven-step method' mode in the clinical application of laparoscopic radical resection of distal gastric cancer".2024Asian journal of surgery
  27. Gastric cancer-induced hemophagocytic lymphohistiocytosis: A case report.2024Asian journal of surgery
  28. Extensive gas accumulation in the gastric wall after chemotherapy combined with target-immunotherapy for gastric adenocarcinoma: A case report.2024Asian journal of surgery
  29. Risk factors for gastroparesis syndrome after radical gastric cancer surgery.2024Asian journal of surgery
  30. Perioperative outcomes of da Vinci robot versus laparoscopic-assisted D2 radical resection of distal gastric cancer with Billroth II anastomosis.2024Asian journal of surgery
  31. Construction of a Cuproptosis-Related Gene Signature for Predicting Prognosis in Gastric Cancer.2024Biochemical genetics
  32. Regulatory mechanisms and potential therapeutic targets in precancerous lesions of gastric cancer: A comprehensive review.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.2024Combinatorial chemistry & high throughput screening
  34. The Role of Cuproptosis Key Factor FDX1 in Gastric Cancer.2024Current pharmaceutical biotechnology
  35. YTHDF2 promotes gastric cancer progression and enhances chemoradiotherapy resistance.2024Drug development research
  36. Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer.2024European journal of medical research免费全文
  37. Network pharmacology and experimental verification: Unraveling Zhiwei Fuwei Pills's role and mechanism in angiogenesis of precancerous lesions of gastric cancer.2024Human & experimental toxicology
  38. Correlation of mir-221-3p differential expression with clinical characteristics of gastric cancer patients.2024Molecular biology reports
  39. MARK4 promotes the malignant phenotype of gastric cancer through the MAPK/ERK signaling pathway.2024Pathology, research and practice
  40. Identification of the whole genome of alternative splicing and RNA-binding proteins involved in nintedanib-induced apoptosis in gastric cancer cells.2024PeerJ免费全文
  41. Proteomic study on nintedanib in gastric cancer cells.2024PeerJ免费全文
  42. Splenectomy versus splenic preservation in total gastrectomy for gastric cancer: a systematic review and meta-analysis comparing survival benefits and short-term complications.2024Postgraduate medicine
  43. Serum extracellular vesicle-derived miR-21-5p and miR-26a-5p as non-invasive diagnostic potential biomarkers for gastric cancer: A preliminary study.2024The International journal of biological markers
  44. Complete clinical response in neoadjuvant treatment of advanced gastric cancer under multidisciplinary treatment mode.2023Asian journal of surgery
  45. Advances in the application of robotic surgical systems to gastric cancer: A narrative review.2023Asian journal of surgery
  46. The safety and feasibility of spleen pull-out lymph node dissection in total gastrectomy: A systematic review and meta-analysis.2023Asian journal of surgery
  47. Glutamate-cysteine ligase catalytic and its modifier function as novel immunotargets in gastric adenocarcinoma.2023Asian journal of surgery
  48. Quercetin inhibits the proliferative effect of gastric cancer cells by activating the pyroptosis pathway.2023Asian journal of surgery
  49. Isolated foot metastasis after radical surgery for gastric cancer: A case report.2023Asian journal of surgery
  50. The Correlation Between 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Semiquantitative Parameters and the Clinical Features and Pathological Biological Indexes of Gastric Cancer.2023Cancer biotherapy & radiopharmaceuticals
  51. Flavonoid-Rich Extract of Oldenlandia diffusa (Willd.) Roxb. Inhibits Gastric Cancer by Activation of Caspase-Dependent Mitochondrial Apoptosis.2023Chinese journal of integrative medicine
  52. MTF1 has the potential as a diagnostic and prognostic marker for gastric cancer and is associated with good prognosis.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  53. Expression and Clinical Significance of PIEZO2 in Gastric Cancer.2023Combinatorial chemistry & high throughput screening
  54. Wilms tumor 1 associated protein promotes epithelial mesenchymal transition of gastric cancer cells by accelerating TGF-β and enhances chemoradiotherapy resistance.2023Journal of cancer research and clinical oncology免费全文
  55. Feasibility of Enhanced Recovery After Surgery Protocols Implemented Perioperatively in Endoscopic Submucosal Dissection for Early Gastric Cancer: A Single-Center Retrospective Study.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  56. Extracellular vesicles, hyperadhesive von willebrand factor, and outcomes of gastric cancer: a clinical observational study.2023Medical oncology (Northwood, London, England)
  57. High-Mobility Group Box 1 Overexpression Predicts a Poor Prognosis and Promotes Epithelial-Mesenchymal Transition in Gastric Cancer by Activating TLR4/NF-κB Signaling.2023Oncology
  58. Clinical characteristics and prognostic nomogram analysis of patients with dual primary cancers with first gastric cancer: a retrospective study in China.2023PeerJ免费全文
  59. PDT for Gastric Cancer - the view from China.2023Photodiagnosis and photodynamic therapy
  60. Safety and Efficacy of Carbon Nanoparticle-Labeled Lymph Node Dissection in Radical Resection of Gastric Cancer: A Systematic Review and Meta-Analysis.2023Technology in cancer research & treatment免费全文
  61. Prognostic significance of N6-methyladenosine-modified related chemotransferase METTL3 in gastric carcinoma: Evidence from meta-analysis.2023The International journal of biological markers
  62. High expression of the circadian clock gene NPAS2 is associated with progression and poor prognosis of gastric cancer: A single-center study.2023World journal of gastroenterology免费全文
  63. Expression of Shh, Gli1, and Cyr61 in Gastric Cancer Predicts Overall Survival of Patients: A Retrospective Study.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  64. S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma.2022Chinese medical journal免费全文
  65. The application of enhanced recovery after surgery in minimally invasive gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials.2022Expert review of gastroenterology & hepatology
  66. Centromeric protein K (CENPK) promotes gastric cancer proliferation and migration via interacting with XRCC5.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  67. Proximal Gastrectomy Versus Total Gastrectomy for Siewert II/III Adenocarcinoma of the Gastroesophageal Junction: a Systematic Review and Meta-analysis.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  68. High FN1 expression correlates with gastric cancer progression.2022Pathology, research and practice
  69. Targeted metabolomic profiles of serum amino acids and acylcarnitines related to gastric cancer.2022PeerJ免费全文
  70. Clinical efficacy and safety of robotic distal gastrectomy for gastric cancer: a systematic review and meta-analysis.2022Surgical endoscopy
  71. Diagnostic values of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in second primary cancers with a gastric primary cancer.2021Asian journal of surgery
  72. Expression and clinical significance of paired- related homeobox 1 and Smad2 in gastric cancer.2021European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  73. A commentary on "Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis" [Int. J. Surg. 73 (2020) 28-41].2021International journal of surgery (London, England)
  74. Contribution of upregulated aminoacyl-tRNA biosynthesis to metabolic dysregulation in gastric cancer.2021Journal of gastroenterology and hepatology免费全文
  75. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.2021Pathology oncology research : POR免费全文
  76. Relationship of ERCC5 genetic polymorphisms with metastasis and recurrence of gastric cancer.2021Revista da Associacao Medica Brasileira (1992)
中文论文(未计入)2
  1. [Zhiwei Fuwei Pills regulate miRNA-21/Bcl-2 pathway to improve mitochondrial apoptosis in rats with precancerous lesions of gastric cancer].2025Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  2. [Primary gastric choriocarcinoma with deletion mutations in the PTEN gene: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  2. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT06949033研究中心III期2025-05 启动
  3. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT06925243研究中心III期2025-04 启动
  4. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  5. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 2220242025: 002025

兰州有 8 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科普外/肝胆胰外科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells.2024AAPS PharmSciTech
  2. Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets.2024Medicine
  3. Osteosarcoma of the sphenoid bone: A case report.2023Asian journal of surgery
  4. Metacarpal osteosarcoma with chest wall metastasis: A case report.2023Asian journal of surgery
  5. The giant retroperitoneal Extraosseous Ewing's sarcoma: A case report.2022Asian journal of surgery
  6. Cinobufagin inhibits tumor progression and reduces doxorubicin resistance by enhancing FOXO1-mediated transcription of FCGBP in osteosarcoma.2022Journal of ethnopharmacology
  7. Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.2021Technology in cancer research & treatment
早期论文(2016–2020 年)5
  1. [Application of apparent diffusion coefficient combined with serum tumor markers detection in evaluating neoadjuvant chemotherapy for osteosarcoma].2020Zhonghua yi xue za zhi
  2. Construction of microRNA-messenger networks for human osteosarcoma.2019Journal of cellular physiology
  3. miR-20a-enhanced cell migration and invasion via ATg5 in osteosarcoma.2019Minerva endocrinologica
  4. miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.2019Yonsei medical journal
  5. Computer-aided discovery and biological characterization of human lactate dehydrogenase 5 inhibitors with anti-osteosarcoma activity.2018Bioorganic & medicinal chemistry letters

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

兰州有 3 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文1
  1. Optimal artificial intelligence model based on gastrointestinal filling contrast-enhanced ultrasound: Risk stratification of gastric gastrointestinal stromal tumors.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
早期论文(2016–2020 年)2
  1. Prognostic impact of preoperative neutrophil-lymphocyte ratio for surgically resected gastrointestinal stromal tumors.2019Medicine
  2. Primary leiomyosarcoma in the colon: A case report.2018Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

兰州有 4 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025

兰州有 3 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层
论文中的科室肿瘤内科
牵头的论文3
  1. Correlation Between Bariatric Surgery and the Risk of Multiple Myeloma: Results from an Evidence-Based Strategy.2024Obesity surgery
  2. LncRNA RP11-1100L3.8 Involves in the Pathogenesis of Multiple Myeloma by Regulating NR4A1.2023Discovery medicine
  3. miR-100-5p is upregulated in multiple myeloma and involves in the pathogenesis of multiple myeloma through targeting MTMR3.2023Hematology (Amsterdam, Netherlands)
中文论文(未计入)7
  1. [The Significance of Bone Marrow Plasma Cell Percentage and Immature Plasma Cells in the Prognosis of Newly Diagnosed Multiple Myeloma Patients].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  3. [Effects of Different Nutritional Scoring Systems on Prognosis of Elderly Patients with Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  4. [Coagulation Indexes and Their Prognostic Significance in Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  5. [The Influence of Serum Homocysteine Level to the Prognosis of Newly Diagnosed Multiple Myeloma Patients and Analysis of Related Factors].2021Zhongguo shi yan xue ye xue za zhi
  6. [Analysis on Related Factors of Pulmonary Infection in Patients with Multiple Myeloma Treated with Bortezomib].2021Zhongguo shi yan xue ye xue za zhi
  7. [Value of Neutrophil/Lymphocyte Ratio and Monocyte/Lymphocyte Ratio in the Prognosis of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

兰州有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题淋巴瘤及肿瘤相关噬血
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

兰州有 2 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

兰州有 2 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Tibiotalocalcaneal arthrodesis for the treatment of ankle joint Charcot disease:a case report].2022Zhongguo gu shang = China journal of orthopaedics and traumatology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

兰州有 2 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

兰州有 3 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

兰州有 2 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
牵头的论文1
  1. Morgagni's Hernia and Duodenal Stenosis Found to Co-Exist in Children with Down's Syndrome: A Case Report.2025Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

兰州有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

甘肃省人民医院

Gansu Provincial Hospital

兰州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Gansu Provincial People's Hospital; Gansu Provincial Hospital of Traditional Chinese Medicine; Gansu Provincial Hospital of TCM; Gansu University of Chinese Medicine (Gansu Provincial Hospital)

提出更正下载数据